ClinicalTrials.gg
TerminatedNCT03532009PRIORITIZE HFUpdated Jun 15, 2021Results posted

Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure

A Phase 2 interventional study of Sodium Zirconium Cyclosilicate and Placebo in Heart Failure, sponsored by AstraZeneca. Terminated at 76 sites in 9 countries. Open to participants aged 18 Years to 150 Years. Per ClinicalTrials.gov, last updated 2021-06-15.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Why this study was terminated
Study stopped early due to the COVID-19 pandemic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years to 150 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 64 studies in Heart Failure by AstraZeneca — 5 open to participants now, 8 under way, 3 of them phase 3. Heart Failure · AstraZeneca.

Enrollment
19th of 39
182 · median 160
Started
2018
with 7 others
Phase 2
8 of 64
none open now
Registered
21st of 64
by date

Among the 64 studies in Heart Failure by AstraZeneca, this one is the 19th largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2018, is one of 8 in phase 2, and was the 21st registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 64 studies in Heart Failure by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 150 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Heart Failure by AstraZeneca, or all of them as a file.
02

Study summary

This is an international, multicentre, parallel-group, randomised, double-blind, placebo controlled, phase II study to evaluate the benefits and risks of using sodium zirconium cyclosilicate (ZS) to initiate and intensify renin angiotensin aldosterone system inhibitor (RAASi) therapy in heart failure patients.

Read the detailed description

Patients with chronic heart failure (NYHA II-IV) and serum potassium > 5.0 mmol/L or at high risk of developing hyperkalaemia will be enrolled. Patients signing informed consent will be screened for up to 14 days. Patients meeting the inclusion criteria, but not the exclusion criteria, are then randomized in a 1:1 ratio to receive ZS or placebo for 3 months while titrating RAASi therapies. Approximately 280 patients will be randomized in the study. Study treatment in this study refers to ZS or placebo, while RAASi therapies are considered background therapy and will not be provided by the study sponsor. Patients will participate in the study for approximately 16 to 18 weeks in total, depending on the duration of the screening period. A Safety Review Committee will be established to review emerging safety data

03

Conditions studied

  • Heart Failure

Keywords

  • Heart Failure
  • Chronic Heart Failure
  • Hyperkalaemia
04

Who can participate

Ages eligible
18 Years to 150 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  2. Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses.
  3. Provision of signed and dated written genetic informed consent prior to collection of sample for genetic analysis. Individuals refusing to provide informed consent for genetic testing may still be included in the study, but will not have to provide samples for genetic analysis.
  4. Subject must be ≥18 years of age inclusive, at the time of signing the informed consent form.
  5. Individuals with established documented diagnosis of symptomatic Heart Failure with Reduced (HFrEF, functional class II-IV), which has been present for at least 3 months.
  6. Individuals with left ventricular ejection fraction ≤ 40% (any measurement made within the past 12 months using echocardiography, multiple gate acquisition scan, computer tomography scanning, magnetic resonance imaging or ventricular angiography is acceptable, provided no subsequent measurement above 40%).
  7. Individuals receiving background standard of care for HFrEF and treated according to locally recognized guidelines with both drugs and devices, as appropriate. Therapy with ACEi/ARB/ARNI, MRA and beta blocker should have been stable for ≥4 weeks. Subjects who are not being treated with beta blockers because of a are eligible. Subjects should be taking no MRA or a low dose of MRA (spironolactone, eplerenone, or canrenone) defined as less than or equal to 12.5 mg once a day (QD) or 25 mg every other day (QOD). If patients are taking a low dose MRA, the rationale for the low dose must be the patient could not tolerate a higher dose due to documented hyperkalemia observed at higher doses.
  8. Individuals with mild hyperkalaemia or at risk of developing hyperkalaemia during the study, as defined by meeting all of the criteria in any one of the 3 categories listed below:

    1. 20-44 ml/min/1.73m2 by CKD-EPI and local lab-K 4.0-5.5 mmol/L inclusive, or
    2. eGFR 45-59 ml/min/1.73m2 by CKD-EPI and local lab-K 5.1-5.5 mmol/L inclusive, or
    3. eGFR 45-59 ml/min/1.73m2 by CKD-EPI and local lab-K 4.0-5.0 mmol/L inclusive and a documented history of S-K > 5.0 mmol/L due to RAASi.
  9. Women of must have a negative pregnancy test during screening (before first dose of IP) performed locally.

Exclusion criteria

Exclusion Criteria:

  1. HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease.
  2. Current acute decompensated HF, hospitalization due to decompensated HF within 4 weeks prior to enrolment, or Myocardial infarction (MI), unstable angina, stroke or (TIA) within 12 weeks prior to enrolment.
  3. Coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) or valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization.
  4. Implantation of a Cardiac Resynchronization Therapy (CRT) device or Implantable Cardioverter Defibrillator (ICD) within 12 weeks prior to enrolment or intent to perform atrial fibrillation ablation or to implant a CRT device.
  5. Previous cardiac transplantation or implantation of a ventricular assistance device (VAD) or similar device, or transplantation or implantation expected after randomization.
  6. Symptomatic bradycardia or second (Mobitz type 2) or third-degree heart block without a pacemaker.
  7. Symptomatic hypotension or systolic blood pressure (BP) \<95 mmHg on 2 consecutive measurements.
  8. Receiving dialysis or anticipated by the investigator to require dialysis therapy within 3 months.
  9. Prior history of to a RAASi drug, including but not limited to development of angioedema, icterus, hepatitis, or neutropenia or thrombocytopenia requiring treatment modification.
  10. Addison's disease or other causes of hypoaldosteronism.
  11. Known hypersensitivity to ZS.
  12. Any condition outside the cardiovascular (CV) and renal disease area, such as but not limited to , with a of less than 2 years based on investigator´s clinical judgement.
  13. Active malignancy requiring treatment.
  14. MRA therapies that are mainly and/or are not widely available as an oral dosing formulation (eg, canrenoate and finerenone) are excluded.
  15. Treated with potassium binding resins such as sodium polystyrene sulfonate (SPS;e.g. Kayexalate®) or calcium polystyrene sulfonate (CPS; e.g. Resonium®) or the cation exchange polymer, patiromer sorbitex calcium (Veltassa®) within 7 days prior to the first dose of study drug.
  16. Treated with potassium supplements within 7 days prior to randomization.
  17. Participation in another clinical study with ZS at any time or treatment with any investigational product (IP) during the last 3 months.
  18. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, AstraZeneca representatives, and/or staff at the study site).
  19. Judgment by the investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions and requirements.
  20. Previous randomisation in the present study.
  21. Subjects with a family history of long syndrome, presence of cardiac arrhythmias or conduction defects that require immediate treatment, or a QTc (corrected QT interval) of ≥550 msec.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    Sodium Zirconium Cyclosilicate (ZS)

    Powder for oral suspension

    Drug: Sodium Zirconium Cyclosilicate

  • Placebo comparator
    Placebo

    Powder for oral suspension

    Drug: Placebo

Interventions

  • Oral use for approximately 3 months

    Also known as: ZS; Lokelma

  • DrugPlacebo

    Oral use for approximately 3 months

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Receiving Different Categories of RAASi Treatments at Month 3

    RAASi treatment categories: * No, or less than target dose, angiotensin converting enzyme inhibitors (ACEi)/ angiotensin receptor blockers (ARB)/ angiotensin receptor/ neprolysin inhibitors (ARNI) and no mineralocorticoid receptor antagonist (MRA); * ACEi/ARB/ARNI at target dose and no MRA; * MRA at less than target dose; * MRA at target dose. Missing values at 3 months were imputed using a multiple imputation approach with 10000 imputations. The imputation model included RAASi category at 3 months as the outcome variable and the following covariates: RAASi category, local lab-K, eGFR and systolic blood pressure measured at the last visit before the 3 months (starting with the randomisation visit) when all the covariates' data were available.

    Time frame: At the end of the treatment visit (Month 3)

Other outcomes

  1. Number of Patients Who Experienced Adverse Events (AEs) During the Study

    An AE is the development of any untoward medical occurrence in a patient or clinical study patient administered an investigational product (IP) and which does not necessarily have a causal relationship with the IP. An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of an IP. A serious adverse event (SAE) is an AE occurring during any study phase, that fulfils one or more of the following criteria: * Results in death; * Is immediately life-threatening; * Requires in-patient hospitalisation or prolongation of existing hospitalisation; * Results in persistent or significant disability or incapacity; * Is a congenital abnormality or birth defect; * Is an important medical event that may jeopardise the patient or may require medical treatment to prevent one of the outcomes listed above.

    Time frame: From Day 1 of treatment up to the end of the follow-up period (Week 17)

  2. Number of Patients Who Experienced Clinically Important Abnormalities in Clinical Laboratory Parameters

    The number of patients who experienced clinically important abnormalities in clinical laboratory assessments as assessed by the Investigator are presented. Clinically important abnormalities in clinical laboratory parameters were reported as AEs. Clinical laboratory assessments included clinical chemistry, haematology and urinalysis performed at the central laboratory.

    Time frame: From Day 1 of treatment up to the end of the follow-up period (Week 17)

  3. Number of Patients Who Experienced Clinically Important Abnormalities in Vital Signs Measurements

    The number of patients who experienced clinically important abnormalities in vital signs assessments as assessed by the Investigator are presented. Clinically important abnormalities in vital signs measurements were reported as AEs. Vital signs assessments included weight, pulse, and systolic and diastolic blood pressure measurements.

    Time frame: From Day 1 of treatment up to the end of the follow-up period (Week 17)

  4. Number of Patients Who Experienced Clinically Significant Changes in Electrocardiogram (ECG) Measurements

    The number of patients who experienced clinically significant changes in ECG measurements as assessed by the Investigator are presented. Clinically important abnormalities in ECG measurements were reported as AEs. 12-lead ECGs were obtained using a digital ECG machine that automatically calculates the heart rate and measures PR, QRS, and QT (using QT interval corrected by Fredericia's algorithm) intervals.

    Time frame: From Day 1 of treatment up to the end of the follow-up period (Week 17)

  5. Number of Patients Who Experienced Low and High S-K Levels

    The S-K levels used for this analysis were based on the measurements obtained by the central laboratory. Patients with S-K levels \< 3.5 mmol/L were considered to have low S-K levels. Patients with S-K levels \> 5.0 mmol/L were considered to have high S-K levels.

    Time frame: From Day 1 of treatment up to the end of the follow-up period (Week 17)

  6. Number of Events of Low and High S-K Levels

    The S-K levels used for this analysis were based on the measurements obtained by the central laboratory. Patients with S-K levels \< 3.5 mmol/L were considered to have had an event of low S-K levels. Patients with S-K levels \> 5.0 mmol/L were considered to have had an event of high S-K levels.

    Time frame: From Day 1 of treatment up to the end of the follow-up period (Week 17)

07

Results

Posted Jun 15, 2021
Limitations and caveats
The study was paused from May to October 2019 to undergo a major protocol amendment. The study was also prematurely terminated due to the COVID-19 pandemic resulting in a reduced sample size and a high premature treatment discontinuation rate.

Participant flow

This study was performed at 64 sites in 9 countries (Brazil, Bulgaria, Canada, Hungary, Poland, Romania, Russia, Slovakia, and the United States of America) between 26 June 2018 and 22 May 2020.

Participant flow — Overall Study
MilestoneSodium Zirconium CyclosilicatePlacebo
Started9290
Received treatment9190
Completed9086
Not completed24
Withdrew: Other11
Withdrew: Death11
Withdrew: Withdrawal by patient02

Outcome measures

PrimaryPercentage of Patients Receiving Different Categories of RAASi Treatments at Month 3

RAASi treatment categories: * No, or less than target dose, angiotensin converting enzyme inhibitors (ACEi)/ angiotensin receptor blockers (ARB)/ angiotensin receptor/ neprolysin inhibitors (ARNI) and no mineralocorticoid receptor antagonist (MRA); * ACEi/ARB/ARNI at target dose and no MRA; * MRA at less than target dose; * MRA at target dose. Missing values at 3 months were imputed using a multiple imputation approach with 10000 imputations. The imputation model included RAASi category at 3 months as the outcome variable and the following covariates: RAASi category, local lab-K, eGFR and systolic blood pressure measured at the last visit before the 3 months (starting with the randomisation visit) when all the covariates' data were available.

Time frame:
At the end of the treatment visit (Month 3)
Reported as:
Number · Percentage of Patients
Percentage of Patients Receiving Different Categories of RAASi Treatments at Month 3
Percentage of PatientsSodium Zirconium CyclosilicatePlacebo
No, or less than target dose ACEi/ARB/ARNI, no MRA14.713.5
ACEi/ARB/ARNI at target dose and no MRA14.715.1
MRA at less than target dose14.224.5
MRA at target dose56.447.0
Statistical analysis
  • Sodium Zirconium Cyclosilicate vs Placebo · F-test · p = 0.426
Other pre-specifiedNumber of Patients Who Experienced Adverse Events (AEs) During the Study

An AE is the development of any untoward medical occurrence in a patient or clinical study patient administered an investigational product (IP) and which does not necessarily have a causal relationship with the IP. An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of an IP. A serious adverse event (SAE) is an AE occurring during any study phase, that fulfils one or more of the following criteria: * Results in death; * Is immediately life-threatening; * Requires in-patient hospitalisation or prolongation of existing hospitalisation; * Results in persistent or significant disability or incapacity; * Is a congenital abnormality or birth defect; * Is an important medical event that may jeopardise the patient or may require medical treatment to prevent one of the outcomes listed above.

Time frame:
From Day 1 of treatment up to the end of the follow-up period (Week 17)
Reported as:
Count of participants · Participants
Number of Patients Who Experienced Adverse Events (AEs) During the Study
ParticipantsSodium Zirconium CyclosilicatePlacebo
Any SAE1410
Any AE leading to discontinuation of IP52
Any AE4347
Other pre-specifiedNumber of Patients Who Experienced Clinically Important Abnormalities in Clinical Laboratory Parameters

The number of patients who experienced clinically important abnormalities in clinical laboratory assessments as assessed by the Investigator are presented. Clinically important abnormalities in clinical laboratory parameters were reported as AEs. Clinical laboratory assessments included clinical chemistry, haematology and urinalysis performed at the central laboratory.

Time frame:
From Day 1 of treatment up to the end of the follow-up period (Week 17)
Reported as:
Count of participants · Participants
Number of Patients Who Experienced Clinically Important Abnormalities in Clinical Laboratory Parameters
ParticipantsSodium Zirconium CyclosilicatePlacebo
Anaemia11
Iron deficiency anaemia10
Hypoglycaemia11
Hypertriglyceridaemia01
Hyponatraemia01
Other pre-specifiedNumber of Patients Who Experienced Clinically Important Abnormalities in Vital Signs Measurements

The number of patients who experienced clinically important abnormalities in vital signs assessments as assessed by the Investigator are presented. Clinically important abnormalities in vital signs measurements were reported as AEs. Vital signs assessments included weight, pulse, and systolic and diastolic blood pressure measurements.

Time frame:
From Day 1 of treatment up to the end of the follow-up period (Week 17)
Reported as:
Count of participants · Participants
Number of Patients Who Experienced Clinically Important Abnormalities in Vital Signs Measurements
ParticipantsSodium Zirconium CyclosilicatePlacebo
Hypotension41
Hypertension20
Hypertensive crisis11
Blood pressure inadequately controlled01
Other pre-specifiedNumber of Patients Who Experienced Clinically Significant Changes in Electrocardiogram (ECG) Measurements

The number of patients who experienced clinically significant changes in ECG measurements as assessed by the Investigator are presented. Clinically important abnormalities in ECG measurements were reported as AEs. 12-lead ECGs were obtained using a digital ECG machine that automatically calculates the heart rate and measures PR, QRS, and QT (using QT interval corrected by Fredericia's algorithm) intervals.

Time frame:
From Day 1 of treatment up to the end of the follow-up period (Week 17)
Reported as:
Count of participants · Participants
Number of Patients Who Experienced Clinically Significant Changes in Electrocardiogram (ECG) Measurements
ParticipantsSodium Zirconium CyclosilicatePlacebo
Number of Patients Who Experienced Clinically Significant Changes in Electrocardiogram (ECG) Measurements00
Other pre-specifiedNumber of Patients Who Experienced Low and High S-K Levels

The S-K levels used for this analysis were based on the measurements obtained by the central laboratory. Patients with S-K levels \< 3.5 mmol/L were considered to have low S-K levels. Patients with S-K levels \> 5.0 mmol/L were considered to have high S-K levels.

Time frame:
From Day 1 of treatment up to the end of the follow-up period (Week 17)
Reported as:
Count of participants · Participants
Number of Patients Who Experienced Low and High S-K Levels
ParticipantsSodium Zirconium CyclosilicatePlacebo
S-K < 3.0 mmol/L00
S-K < 3.5 mmol/L70
S-K > 5.5 mmol/L2332
S-K > 6.0 mmol/L34
Other pre-specifiedNumber of Events of Low and High S-K Levels

The S-K levels used for this analysis were based on the measurements obtained by the central laboratory. Patients with S-K levels \< 3.5 mmol/L were considered to have had an event of low S-K levels. Patients with S-K levels \> 5.0 mmol/L were considered to have had an event of high S-K levels.

Time frame:
From Day 1 of treatment up to the end of the follow-up period (Week 17)
Reported as:
Number · Events
Number of Events of Low and High S-K Levels
EventsSodium Zirconium CyclosilicatePlacebo
S-K < 3.0 mmol/L00
S-K < 3.5 mmol/L120
S-K > 5.5 mmol/L3759
S-K > 6.0 mmol/L34

Adverse events

Collected over From Day 1 of treatment up to the end of the follow-up period (Week 17). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sodium Zirconium Cyclosilicate1/91 (1.1%)14/91 (15.4%)16/91 (17.6%)
Placebo1/90 (1.1%)10/90 (11.1%)7/90 (7.8%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventSodium Zirconium CyclosilicatePlacebo
Cardiac failure chronicCardiac disorders2/912/90
Acute myocardial infarctionCardiac disorders2/911/90
Cardiac failure acuteCardiac disorders2/911/90
BronchitisInfections and infestations0/911/90
OsteomyelitisInfections and infestations0/911/90
PneumoniaInfections and infestations1/911/90
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/911/90
HyponatraemiaMetabolism and nutrition disorders0/911/90
SyncopeNervous system disorders0/911/90
Angina unstableCardiac disorders0/911/90
Most frequent other events
Most frequent other events
EventSodium Zirconium CyclosilicatePlacebo
Cardiac failure chronicCardiac disorders7/912/90
Viral upper respiratory tract infectionInfections and infestations6/913/90
Chronic kidney diseaseRenal and urinary disorders5/913/90

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sodium Zirconium CyclosilicatePlaceboTotal
Mean72.9 ± 8.871.0 ± 8.171.9 ± 8.5
Age, Customized
Age, Customized(Participants)Sodium Zirconium CyclosilicatePlaceboTotal
≤ 17 years000
18 - 64 years171633
65 - 84 years6569134
≥ 85 years10515
Sex: Female, Male
Sex: Female, Male(Participants)Sodium Zirconium CyclosilicatePlaceboTotal
Female413374
Male5157108
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sodium Zirconium CyclosilicatePlaceboTotal
Hispanic or Latino151429
Not Hispanic or Latino7776153
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sodium Zirconium CyclosilicatePlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American112
White9089179
More than one race000
Unknown or Not Reported000
S-K Concentration
S-K Concentration(Participants)Sodium Zirconium CyclosilicatePlaceboTotal
≤ 5.0 mmol/L6567132
> 5.0 mmol/L272350
New York Heart Association (NYHA) Functional Classification
New York Heart Association (NYHA) Functional Classification(Participants)Sodium Zirconium CyclosilicatePlaceboTotal
Class I000
Class II6157118
Class III313364
Class IV000
Left Ventricular Ejection Fraction (LVEF)
Left Ventricular Ejection Fraction (LVEF)(LVEF Percentage)Sodium Zirconium CyclosilicatePlaceboTotal
Mean33.8 ± 5.833.9 ± 6.133.8 ± 6.0

1 further baseline measures are reported on the registry.

08

Study locations

76 sites
  • Research Site
    National City, California 91950, United States
  • Research Site
    Stanford, California 94305, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Miami, Florida 33133, United States
  • Research Site
    New Smyrna Beach, Florida 32169, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Alexandria, Louisiana 71301, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Brooklyn, New York 11204, United States
  • Research Site
    Wyomissing, Pennsylvania 19610, United States
  • Research Site
    Rapid City, South Dakota 57701, United States
  • Research Site
    El Paso, Texas 79935, United States
  • Research Site
    Belo Horizonte, 30140 062, Brazil
  • Research Site
    Belo Horizonte, 30150-240, Brazil
  • Research Site
    Brasillia, 70200-730, Brazil
  • Research Site
    Campina Grande do Sul, 83430000, Brazil
  • Research Site
    Campinas, 13060-080, Brazil
  • Research Site
    Curitiba, 80010-030, Brazil
  • Research Site
    Marília, 17515000, Brazil
  • Research Site
    Porto Alegre, 90020090, Brazil
  • Research Site
    Rio de Janeiro, 20241-180, Brazil
  • Research Site
    Santo Andre, 09090-790, Brazil
  • Research Site
    Sao Paulo, 05403-000, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    Uberlandia, 38411-186, Brazil
  • Research Site
    Votuporanga, 15500-003, Brazil
  • Research Site
    Plovdiv, 4003, Bulgaria
  • Research Site
    Shumen, 9700, Bulgaria
  • Research Site
    Sofia, 1202, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Montreal, Quebec H1T 1C8, Canada
  • Research Site
    Saint-Charles-Borromee, Quebec J6E 6J2, Canada
  • Research Site
    Trois-Rivieres, Quebec G8Z 3R9, Canada
  • Research Site
    Quebec, G1V 4G5, Canada
  • Research Site
    Baja, 6500, Hungary
  • Research Site
    Budapest, 1051, Hungary
  • Research Site
    Budapest, 1096, Hungary
  • Research Site
    Budapest, 1106, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Budapest, 1204, Hungary
  • Research Site
    Hatvan, 3000, Hungary
  • Research Site
    Kecskemét, 6000, Hungary
  • Research Site
    Miskolc, 3529, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Pécs, 7623, Hungary
  • Research Site
    Szentes, 6600, Hungary
  • Research Site
    Chorzów, 41-500, Poland
  • Research Site
    Gdańsk, 80-952, Poland
  • Research Site
    Legnica, 59-220, Poland
  • Research Site
    Poznań, 60-848, Poland
  • Research Site
    Rzeszów, 35-055, Poland
  • Research Site
    Tczew, 83-110, Poland
  • Research Site
    Brasov, 500283, Romania
  • Research Site
    Bucuresti, 042122, Romania
  • Research Site
    Cluj Napoca, 400001, Romania
  • Research Site
    Craiova, 200642, Romania
  • Research Site
    Sibiu, 550245, Romania
  • Research Site
    Tg Mures, 540143, Romania
  • Research Site
    Aramil, 624002, Russian Federation
  • Research Site
    Ekaterinburg, 620039, Russian Federation
  • Research Site
    Krasnoyarsk, 660062, Russian Federation
  • Research Site
    Moscow, 121552, Russian Federation
  • Research Site
    Novosibirsk, 630055, Russian Federation
  • Research Site
    Perm, 614000, Russian Federation
  • Research Site
    Ryazan, 390039, Russian Federation
  • Research Site
    Saint Petersburg, 191015, Russian Federation
  • Research Site
    Tver, 170036, Russian Federation
  • Research Site
    Yaroslavl, 150062, Russian Federation
  • Research Site
    Brezno, 97742, Slovakia
  • Research Site
    Lucenec, 984 01, Slovakia
  • Research Site
    Presov, 080 01, Slovakia
  • Research Site
    Svidnik, 08901, Slovakia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in May 2020, 22 months.

Results were first posted in Jun 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2018
First posted
May 22, 2018
StartActual
Jun 26, 2018
Primary completionActual
May 22, 2020
CompletionActual
May 22, 2020
Results first posted
Jun 15, 2021
Last update
Jun 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03532009
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 22, 2018
Start date
Jun 26, 2018
Primary completion
May 22, 2020
Completion
May 22, 2020
Results posted
Jun 15, 2021
Last update
Jun 15, 2021

Study contacts

Jean-Claude Tardif
principal investigator · Montreal Heart Institute 5000 Belanger Street, Montreal, PQ Canada H1T1C8

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium zirconium cyclosilicate

Start the discussion